Android app on Google Play

UPDATE: UBS Upgrades Amgen (AMGN) to Buy; Pipeline Visibility Higher

September 10, 2012 7:38 AM EDT Send to a Friend
Get Alerts AMGN Hot Sheet
Price: $140.71 +0.99%

Rating Summary:
    14 Buy, 14 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 14 | New: 38
Trade AMGN Now!
Join SI Premium – FREE
(Updated - September 10, 2012 12:22 PM EDT)

UBS upgraded Amgen (NASDAQ: AMGN) from Neutral to Buy. PT raised from $80 to $96.

Analyst, Matthew Roden, said, "Our previous Neutral rating on the industry bellwether had been predicated on an anemic topline growth profile, and a lack of visibility into clear revenue growth drivers in the pipeline. We now take a more constructive outlook ahead of phase 2 data for AMG 145 (lipid-lowering) and AMG 785 (bone health)."

FY13 EPS estimate raised from $6.27 to $6.81.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $83.96 yesterday.




You May Also Be Interested In


Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Upgrades

Related Entities

UBS

Add Your Comment